Home | Terms of Use | Privacy Statement | Contact Us For U.S. healthcare professionals only.
		Contact Us   Video Watch a Biological  Video online...   We hope this site provides you with valuable information regarding Kepivance® (palifermin). Ordering Info For ordering please see biovitrum.com E-mail Us Information: medical.info@biovitrum.com Call Us Please note that all Toll Free Numbers listed does not work across all mobile phone providers. Alternative numbers are therefore listed below. Australia 1-800-086468 Austria +800 386 587 21 Belgium +800 386 587 21 Canada 866-773-5274 Cyprus +800 386 587 21 Czech Republic +800 386 587 21 Denmark +800 386 587 21 Estonia +800 386 587 21 Finland +800 386 587 21 France +800 386 587 21 Germany +800 386 587 21 Greece +800 386 587 21 Hungary +800 386 587 21 Iceland +800 386 587 21 Ireland +800 386 587 21 Italy +800 386 587 21 Japan +800 386 587 21 Latvia +800 386 587 21 Lithuania +800 386 587 21 Luxembourg +800 386 587 21 Netherlands +800 386 587 21 New Zealand 0800-446286 Norway +800 386 587 21 Poland +800 386 587 21 Portugal +800 386 587 21 Slovakia +800 386 587 21 Slovenia +800 386 587 21 Spain +800 386 587 21 Sweden +46 8 697 20 00* or +800 386 587 21 Switzerland +800 386 587 21 UK +800 386 587 21 USA 866-773-5274 *Not toll free Alternative Numbers Select language. Please note that these are not Toll Free Numbers! English: +41 61 564 13 28 German: +41 61 564 13 29 French: +41 61 564 13 30 Italian: +41 61 564 13 31 Spanish: +41 61 564 13 32 ABOUT ORAL MUCOSITIS ABOUT KEPIVANCE® TOOLS AND RESOURCES FOR NURSES FOR PHARMACISTS IMPORTANT PRODUCT SAFETY INFORMATION
	Kepivance® is indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support. The safety and efficacy of Kepivance® have not been established in patients with non-hematologic malignancies. Important Safety Information In patients with hematologic malignancies, the most common serious adverse reaction in clinical trials attributed to Kepivance® was skin rash reported in less than 1% of patients.   Contact | Reimbursement | Biovitrum.com | Site Map Prescribing Information © 2008 Biovitrum AB (publ). All rights reserved.